A clinical study on adding detemir or glargine in not well-controlled type 2 diabetes

Objective To compare the efficacy and safety between basal insulin analogues detemir and glargine in type 2 diabetes.Methods Six-two diabetic patients were randomized to two groups of receiving insulin detemir (n = 31) or glargine (n = 31)once daily (at bedtime) for 3 months.Results HbA_1 c decreased from 8.6% to 7.0% (detemir) and 8.6% to 6.9% (glargine).FPG decreased from 8.9 to 7.0 and 9.0 to 6.8mmol/L,respectively.PPG decreased from 13.3 to 8.8 and 13.5 to 8.9mmol/L, respectively.There was no statistical difference between two groups (P0.05).6.5% patients in both detemir and glargine experienced hypoglycemia.Weight gain was lower in detemir than in glargine group (P0.01).Dosage in both groups were around 0.4～0.5 U/kg.Conclusions Addition of insulin detemir or glargine to oral hypoglycemic agents achieves clinically important improvements in glycaemic control with low risk of hypoglycaemia.Treatment with detemir will achieve extra benefit in reducing weight gain.